* Avanos Medical Inc AVNS.N AVNS.K is expected to show a
rise
in quarterly revenue when it reports results on November 2.
* The Alpharetta Georgia-based company is expected to
report a
11.6% increase in revenue to $205.467 million from $184.1
million a year ago, according to the mean estimate from 3
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Avanos Medical Inc
is for
earnings of 35 cents per share.
* The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 2
"hold" and 1 "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Avanos
Medical
Inc is $31, above its last closing price of $21.75.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Jun. 30 2022 0.38 0.38 0.41 Beat 7.3
Mar. 31 2022 0.26 0.26 0.26 Met 0
Dec. 31 2021 0.40 0.40 0.46 Beat 14.4
Sep. 30 2021 0.29 0.30 0.25 Missed -17.1
Jun. 0.23 0.23 0.21 Missed -10
30 2021
Mar. 31 2021 0.18 0.19 0.23 Beat 24.3
Dec. 31 2020 0.22 0.22 0.28 Beat 29.2
Sep. 30 2020 0.11 0.10 0.21 Beat 110
This summary was machine generated October 28 at 15:57 GMT. All
figures in US dollars unless otherwise stated